The discovery that dysregulation in the KIT tyrosine kinase activity underlies the pathogenesis of GIST has led to the development of a novel systemic tyrosine kinase inhibitor, imatinib[5]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.